Negotiation Timeline

  • Initiation

    A drug is identified and brought into a pCPA process (see standard negotiation process or expedited negotiation pathways).

  • Consideration

    The pCPA considers the evidence (including HTA reimbursement recommendations) and gathers other data to inform the negotiation approach, in alignment with the needs of public drug plans. This phase concludes when the pCPA sends a letter of engagement to the manufacturer. 

    Letter of engagement sent to manufacturer

    This lets the manufacturer know the pCPA is ready to start negotiating.

  • Negotiation

    The pCPA negotiation team reaches out to the manufacturer to outline next steps, then we exchange offers to try to reach an agreement on terms and funding conditions.

  • Completion

    The pCPA creates a letter of intent outlining negotiated terms. If the negotiation ended without an agreement, the pCPA sends a letter letting the manufacturer know that the negotiation is closed. 

    Negotiation process concluded

Related negotiations

Verzenio (abemaciclib)

Status:

Concluded with an LOI

Manufacturer:

Eli Lilly Canada Inc.

Indication:

Early breast cancer, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, at high risk of disease recurrence based on clinicopathological features and a Ki-67 score ?20%,for the adjuvant treatment of adult patients (in combination with endocrine therapy)

Last updated:

July 18, 2023

Verzenio (abemaciclib)

Status:

Concluded with an LOI

Manufacturer:

Eli Lilly Canada Inc.

Indication:

In combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based on clinicopathological features

Last updated:

October 25, 2024

Verzenio (abemaciclib)

Status:

Concluded with an LOI

Manufacturer:

Eli Lilly Canada Inc.

Indication:

For the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer as follows: - in combination with an aromatase inhibitor in postmenopausal women as initial endocrine-based therapy. - in combination with fulvestrant in women with disease progression following endocrine therapy. Pre- or perimenopausal women must also be treated with a gonadotropin-releasing hormone (GnRH) agonist. - as a single agent in women with disease progression following endocrine therapy and at least 2 prior chemotherapy regimens. At least one chemotherapy...

Last updated:

April 8, 2026

Verzenio (abemaciclib)

Status:

Concluded with an LOI

Manufacturer:

Eli Lilly Canada Inc.

Indication:

For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor (AI) in postmenopausal women as initial endocrine-based therapy.

Last updated:

April 8, 2026